News Amgen in $1.9bn swoop for Five Prime and its gastric cancer ... Amgen is to buy US biotech Five Prime Therapeutics for around $1.9 billion, adding a potential gastric cancer drug to its pipeline.
News Five Prime eyes financing after positive results with stomac... Shares in US biotech Five Prime Therapeutics more than tripled after it reported promising trial results with stomach cancer drug candidate bemarituzumab, returning the stock to levels not
Market Access The changing landscape of drug clinical assessment: Tommy Br... In a new pharmaphorum podcast, Tommy Bramley, SVP of market access and healthcare consulting at Cencora, discusses Joint Clinical Assessments.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face